TD Asset Management Inc. decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.8% during the second quarter, Holdings Channel reports. The fund owned 70,366 shares of the medical equipment provider’s stock after selling 5,112 shares during the period. TD Asset Management Inc.’s holdings in Zimmer Biomet Holdings were worth $9,035,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. increased its position in shares of Zimmer Biomet Holdings by 4,042.4% in the first quarter. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider’s stock worth $2,044,168,000 after buying an additional 16,336,262 shares during the last quarter. Harbour Capital Advisors LLC increased its position in shares of Zimmer Biomet Holdings by 13,131.3% in the second quarter. Harbour Capital Advisors LLC now owns 1,302,618 shares of the medical equipment provider’s stock worth $10,145,000 after buying an additional 1,292,773 shares during the last quarter. Nordea Investment Management AB increased its position in shares of Zimmer Biomet Holdings by 25.0% in the first quarter. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider’s stock worth $602,159,000 after buying an additional 987,398 shares during the last quarter. Glenview Capital Management LLC bought a new position in shares of Zimmer Biomet Holdings during the first quarter worth approximately $94,197,000. Finally, Point72 Asset Management L.P. increased its position in shares of Zimmer Biomet Holdings by 230.3% in the first quarter. Point72 Asset Management L.P. now owns 1,053,500 shares of the medical equipment provider’s stock worth $128,643,000 after buying an additional 734,500 shares during the last quarter. Hedge funds and other institutional investors own 82.84% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (NYSE ZBH) opened at 112.97 on Wednesday. Zimmer Biomet Holdings, Inc. has a one year low of $95.63 and a one year high of $133.49. The stock has a market capitalization of $22.84 billion, a P/E ratio of 32.18 and a beta of 1.20. The stock’s 50 day moving average price is $124.00 and its 200 day moving average price is $121.30.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing analysts’ consensus estimates of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The company had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. During the same period last year, the firm earned $2.02 earnings per share. The firm’s revenue for the quarter was up 1.1% on a year-over-year basis. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Friday, September 22nd will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 27.59%.

TRADEMARK VIOLATION WARNING: “TD Asset Management Inc. Sells 5,112 Shares of Zimmer Biomet Holdings, Inc. (ZBH)” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/td-asset-management-inc-sells-5112-shares-of-zimmer-biomet-holdings-inc-zbh/1493447.html.

ZBH has been the subject of several recent analyst reports. Needham & Company LLC increased their price target on Zimmer Biomet Holdings from $151.00 to $153.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 price target on Zimmer Biomet Holdings and gave the stock a “buy” rating in a research note on Friday, April 28th. Goldman Sachs Group, Inc. (The) initiated coverage on Zimmer Biomet Holdings in a research note on Tuesday, May 16th. They issued a “sell” rating and a $92.00 price target for the company. Wells Fargo & Company cut Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a research note on Friday, April 28th. Finally, Zacks Investment Research cut Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $136.90.

In related news, insider Sang Yi sold 17,731 shares of Zimmer Biomet Holdings stock in a transaction on Monday, June 12th. The stock was sold at an average price of $124.56, for a total transaction of $2,208,573.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Tony W. Collins sold 16,986 shares of Zimmer Biomet Holdings stock in a transaction on Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The disclosure for this sale can be found here. 1.07% of the stock is owned by insiders.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.